Dexpramipexole is ineffective in two models of ALS related neurodegeneration

Authors :: Finkbeiner, Steven
Finkbeiner, Steven
Vieira, FG
LaDow, E
Moreno, A
Kidd, JD
Levine, B
Thompson, K
Gill, A
Perrin, S
Finkbeiner, Steven
Finkbeiner, Steven
Vieira, FG
LaDow, E
Moreno, A
Kidd, JD
Levine, B
Thompson, K
Gill, A
Perrin, S
Publication Year :: 2014
Abstract: © 2014 Vieira et al.Treatment options for people living with amyotrophic lateral sclerosis (ALS) are limited and ineffective. Recently, dexpramipexole (RPPX) was advanced into human ALS clinical trials. In the current studies, we investigated RPPX in two p

Tools